The landmark advancement in MM therapy was the development and approval of the monoclonal antibodies elotuzumab (anti-SLAMF7) and daratumumab (anti-CD38) in 2015 for both monotherapy and combination forms, particularly in the case of RRMM [296,297,298,299,300,301]. The gene discussed is SLAMF7; the disease is Miyoshi myopathy.